- Business Wire•8 hours agoAlnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today initial data from its ongoing Phase 1/2 study with ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1 .
- Business Wire•3 days ago
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it has granted stock options to Yvonne Greenstreet, the Company's newly appointed Chief Operating Officer.
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||63.00 x 200|
|Ask||86.12 x 300|
|Day's Range||75.56 - 77.75|
|52wk Range||49.96 - 110.75|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-17.83|
|Avg Vol (3m)||700,503|
|Dividend & Yield||N/A (N/A)|